Rubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforce

Rubius Therapeutics (RUBY) said it was discontinuing ongoing trials of RTX-240 and RTX-224 for advanced solid tumors and was reducing its workforce by 75%. Rubius is restructuring...

Related Keywords

Rhode Island ,United States ,Smithfield ,Pablo Cagnoni ,Klaus Vedfelt , ,Red Cell Therapeutics ,Rubius President ,